Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive hiv-infected patients

HIV Clinical Trials

Volumn 15, Issue 1, 2014, Pages 1-13

  Calza, Leonardo ^a   Vanino, Elisa ^a   Salvadori, Caterina ^a   Manfredi, Roberto ^a   Colangeli, Vincenzo ^a   Cascavilla, Alessandra ^a   Di Bari, Maria ^a   Motta, Roberto ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

antiretroviral therapy; hypercholesterolemia; inflammation; markers; statins

Indexed keywords

ANTIRETROVIRAL THERAPY; HYPERCHOLESTEROLEMIA; INFLAMMATION; MARKERS; STATINS;

ADENINE; ADULT; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; OXAZINES; PYRIMIDINES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894167985     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1501-1     Document Type: Article

References (42)

1. Baigent C Keech A Kearney PM et al. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Lamon-Fava S. Statins and lipid metabolism: An update. Curr Opin Lipidol. 2013;24: 221-226.
3. Peters SA Palmer MK Grobbee DE et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010;268:155-161.
4. Ridker PM Danielson E Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
5. Zhou Q Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J. 2010;74: 818-826.
6. Ota H Eto M Kano MR et al. Induction of endothelial nitric oxide synthase SIRT1 and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010;30:2205-2211.
7. Antoniades C Bakogiannis C Tousoulis D et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010;122:S66-S73.
8. Jougasaki M Ichiki T Takenoshita Y et al. Statins suppress interleukin-6-induced monocyte chemo-Attarctant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010;159:1294-1303.
9. Merx MW Liehn EA Janssens U et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004;109:2560-2565. (Pubitemid 38720557)
10. Rosch JW Boyd AR Hinojosa E et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest. 2010;120:627-635.
11. Amuro H Ito T Miyamoto R et al. Statins inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase function as inhibitors of cellular and molecular components involved in type 1 interferon production. Arthritis Rheum. 2010;62:2073-2085.
12. Risk assessment tool for estimation 10-year risk of developing hard CHD (myocardial infarction and coronary death). http://hp2010.nhlbihin.net/atpiii/ calculator. asp?usertype=prof
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Ther. Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
14. Kuller LH Tracy R Belloso W et al. Inflammation and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
15. Duprez DA Neuhaus J Kuller LH et al. Inflammation coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
16. Triant VA Meigs JB Grinspoon SK. Association of C- reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273.
17. Tien PC Choi AI Zolopa AR et al. Infl ammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316-322.
18. Mangili A Polak JF Quach LA Gerrior J Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis. 2011;214:468-473.
19. McDonald B Moyo S Gabaitiri L et al. Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: Results from a clinical trial. AIDS Res Hum Retroviruses. 2013;29:993-999.
20. Lau B Sharrett AR Kingsley LA et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64-70. (Pubitemid 43063843)
21. Feldman JG Goldwasser P Holman S DeHovitz J Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquire Immune Defic Syndr. 2003;32:210-214. (Pubitemid 36222724)
22. Bu D Griffin G Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22:165-170.
23. Quist-Paulsen P. Statins and inflammation: An update. Curr Opin Cardiol. 2010;25:399-405.
24. Jones PH Davidson MH Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160. (Pubitemid 36835963)
25. Schuster H Barter PJ Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147:705-712. (Pubitemid 38900464)
26. Crouse JR Raichlen JS Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. JAMA. 2007;297:1344-1353. (Pubitemid 46513235)
27. Tawakol A Fayad ZA Mogg R et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic infl ammation: Results of a multi-center FDG-PET/CT feasibility study [published online ahead of print May 30 2013]. J Am Coll Cardiol.
28. Liu B Zhang JY Cao HM et al. Effect of rosuvastatin on ROCK activity endothelial function and inflammation in Asian patients with atherosclerosis. Intern Med. 2012;51:1177-1182.
29. Maziere JC Landureau JC Giral P et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother. 1994;48:63-67. (Pubitemid 24113551)
30. Giguere JF Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-Associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol. 2004;78:12062-12065. (Pubitemid 39390792)
31. Moncunill G Negredo E Bosch L et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005;19:1697-1700. (Pubitemid 41502686)
32. Amet T Nonaka M Dewan MZ et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008;10:471-480.
33. Negredo E Clotet B Puig J et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS. 2006;20:619-621. (Pubitemid 43731608)
34. Sklar PA Masur H Grubb JR et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS. 2005;19: 1109-1111. (Pubitemid 40961155)
35. Ganesan A Crum-Cianflone N Higgins J et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-764.
36. Aslangul E Fellahi S Assoumou LK et al. High-sensitivity C-reactive protein levels fall during statin therapy in HIVinfected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25:1128-1131.
37. Calza L Trapani F Bartoletti M et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13:153-161.
38. Fichtenbaum CJ Evans SE Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS. 2011;25:2053.
39. De Wit S Delforge M Necsoi CV Clumeck N. Down regulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25: 1332-1333.
40. Moore RD Bartlett JG Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIVinfected patients. PLoS One. 2011;6:e21843.
41. Rasmussen LD Kronborg G Larsen CS Pedersen C Gerstoft J Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828.
42. Higuita EA Jaimes FA Rugeles MT Montoya CJ. In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4 [published online ahead of print May 1 2013]. AIDS Res Ther.